Cryo-Cell International Q3 Profit Drops 25%, Revenue Falls 3%

Cryo-Cell International Inc reported a Q3 profit of $0.75 million, or $0.09 per share, a drop from $1.05 million, or $0.13 per share in the same period last year. Revenue fell 3.0% to $7.83 million from $8.07 million.

Cryo-Cell International Inc. (CCEL) reported its fiscal third-quarter earnings for the period ended August 31, 2025, with a net income of $0.75 million, or $0.09 per share, down from $1.05 million, or $0.13 per share in the same period last year, according to a Business Wire release. The company's revenue fell 3.0% to $7.83 million from $8.07 million.

The decrease in revenue can be attributed to a 14% decrease in the number of new domestic cord blood specimens processed, which resulted in an 11% decrease in the cost of sales from $5.64 million to $5.08 million, according to the company's SEC 10-Q filing. Selling, general, and administrative expenses increased by 2% to $12.77 million, primarily due to an increase in legal fees related to ongoing legal proceedings.

Cryo-Cell's research, development, and related engineering expenses significantly reduced from $0.94 million to $0.29 million, reflecting a strategic pause in investments related to the Duke License Agreement dispute. Interest expense increased to $1.58 million from $1.12 million, primarily due to increased interest related to credit and subordination agreements. Income taxes decreased to $0.91 million from $1.38 million, reflecting changes in deferred tax assets and liabilities.

Despite the challenges, Cryo-Cell remains focused on maximizing growth potential through superior quality services and product differentiation. The company anticipates leveraging its expertise in biological specimen handling to expand its service offerings and enhance its competitive position in the stem cell industry.